Rilotumumab Potential for MET-Expressing Gastric Cancer

Phase Ib/II study results indicate rilotumumab may be effective for treating gastric and oesophagogastric cancer expressing MET...

ESMO members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.